Literature DB >> 20462604

Role of COX-2 in tumorospheres derived from a breast cancer cell line.

Balraj Singh1, Kendra R Cook, Laura Vincent, Carolyn S Hall, Cecilia Martin, Anthony Lucci.   

Abstract

BACKGROUND: Cyclooxygenase-2 (COX-2) expression in primary breast cancer predicts tumor cell dissemination to bone marrow, which is a risk factor for recurrence and distant metastasis. "Stem-like" phenotype may be important in cancer metastasis.
METHODS: To investigate the role of COX-2 protein in breast cancer stem-like cells, we analyzed it by co-immunofluorescence in tumorospheres derived from the MCF7 estrogen receptor-positive breast cancer cell line. To evaluate COX-2 function we utilized a COX-2 inhibitor in a clonogenicity assay performed with tumorospheres-derived cells.
RESULTS: We detected rare cells in tumorospheres (one cell per tumorosphere) with very high COX-2 expression (COX-2(high)). COX-2 transfected MCF7 cells were able to generate long-term tumorospheres culture, even though transfection efficiency was only one in a million cells. We detected expression of OCT4 in some COX-2(high) cells, supporting the hypothesis that these cells could be cancer stem-like cells. It is important that COX-2(high) cells showed less expression of Ki-67 than did neighboring cells, indicating that COX-2(high) cells may be progenitors of tumorospheres. Celecoxib inhibited the growth of tumorosphere cultures and the ability of tumorosphere-derived cells to form colonies in vitro, indicating an active role of COX-2 in these processes. However, 2 μM celecoxib failed to eradicate tumorosphere-initiating cells. Finally, we detected rare COX-2(high) cells among SUM149 inflammatory breast cancer cells growing on plastic in serum-containing medium; the SUM149 cell line produces a very high level of COX-2 protein.
CONCLUSION: Our results support a role for COX-2 in stem-like breast cancer cells and suggest a mechanism behind a role for COX-2 in disseminated tumor cells, which are known to exhibit characteristic biomarkers and functional properties of stem-like cells.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20462604      PMCID: PMC2921551          DOI: 10.1016/j.jss.2010.03.003

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  37 in total

1.  In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells.

Authors:  Gabriela Dontu; Wissam M Abdallah; Jessica M Foley; Kyle W Jackson; Michael F Clarke; Mari J Kawamura; Max S Wicha
Journal:  Genes Dev       Date:  2003-05-15       Impact factor: 11.361

2.  Colocalization and interaction of cyclooxygenase-2 with caveolin-1 in human fibroblasts.

Authors:  J Y Liou; W G Deng; D W Gilroy; S K Shyue; K K Wu
Journal:  J Biol Chem       Date:  2001-06-29       Impact factor: 5.157

3.  Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties.

Authors:  Dario Ponti; Aurora Costa; Nadia Zaffaroni; Graziella Pratesi; Giovanna Petrangolini; Danila Coradini; Silvana Pilotti; Marco A Pierotti; Maria Grazia Daidone
Journal:  Cancer Res       Date:  2005-07-01       Impact factor: 12.701

4.  Metastasis results from preexisting variant cells within a malignant tumor.

Authors:  I J Fidler; M L Kripke
Journal:  Science       Date:  1977-08-26       Impact factor: 47.728

5.  Prospective identification of tumorigenic breast cancer cells.

Authors:  Muhammad Al-Hajj; Max S Wicha; Adalberto Benito-Hernandez; Sean J Morrison; Michael F Clarke
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-10       Impact factor: 11.205

6.  COX-2 overexpression increases motility and invasion of breast cancer cells.

Authors:  Balraj Singh; Jacob A Berry; Angela Shoher; Vijay Ramakrishnan; Anthony Lucci
Journal:  Int J Oncol       Date:  2005-05       Impact factor: 5.650

7.  Subcellular localization of prostaglandin endoperoxide H synthases-1 and -2 by immunoelectron microscopy.

Authors:  A G Spencer; J W Woods; T Arakawa; I I Singer; W L Smith
Journal:  J Biol Chem       Date:  1998-04-17       Impact factor: 5.157

8.  COX-2 induces IL-11 production in human breast cancer cells.

Authors:  Balraj Singh; Jacob A Berry; Angela Shoher; Anthony Lucci
Journal:  J Surg Res       Date:  2006-02-02       Impact factor: 2.192

9.  A pooled analysis of bone marrow micrometastasis in breast cancer.

Authors:  Stephan Braun; Florian D Vogl; Bjørn Naume; Wolfgang Janni; Michael P Osborne; R Charles Coombes; Günter Schlimok; Ingo J Diel; Bernd Gerber; Gerhard Gebauer; Jean-Yves Pierga; Christian Marth; Daniel Oruzio; Gro Wiedswang; Erich-Franz Solomayer; Günther Kundt; Barbara Strobl; Tanja Fehm; George Y C Wong; Judith Bliss; Anne Vincent-Salomon; Klaus Pantel
Journal:  N Engl J Med       Date:  2005-08-25       Impact factor: 91.245

10.  Histologically normal human mammary epithelia with silenced p16(INK4a) overexpress COX-2, promoting a premalignant program.

Authors:  Yongping G Crawford; Mona L Gauthier; Anita Joubel; Kristin Mantei; Krystyna Kozakiewicz; Cynthia A Afshari; Thea D Tlsty
Journal:  Cancer Cell       Date:  2004-03       Impact factor: 31.743

View more
  18 in total

Review 1.  Microbiome, bile acids, and obesity: How microbially modified metabolites shape anti-tumor immunity.

Authors:  Laura M Sipe; Mehdi Chaib; Ajeeth K Pingili; Joseph F Pierre; Liza Makowski
Journal:  Immunol Rev       Date:  2020-05       Impact factor: 12.988

2.  Overexpression of COX-2 in celecoxib-resistant breast cancer cell lines.

Authors:  Balraj Singh; LaTashia R Irving; Karen Tai; Anthony Lucci
Journal:  J Surg Res       Date:  2010-05-26       Impact factor: 2.192

3.  Hepatocyte growth factor induces breast cancer cell invasion via the PI3K/Akt and p38 MAPK signaling pathways to up-regulate the expression of COX2.

Authors:  Wenbin Kuang; Qiuchan Deng; Chuntao Deng; Wensheng Li; Shaowei Shu; Meirong Zhou
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

4.  The potential role of COX-2 in cancer stem cell-mediated canine mammary tumor initiation: an immunohistochemical study.

Authors:  Jian Huang; Di Zhang; Fuqiang Xie; Degui Lin
Journal:  J Vet Sci       Date:  2015-06-17       Impact factor: 1.672

5.  Prostaglandin E2 receptor EP4 as the common target on cancer cells and macrophages to abolish angiogenesis, lymphangiogenesis, metastasis, and stem-like cell functions.

Authors:  Mousumi Majumder; Xiping Xin; Ling Liu; Gannareddy V Girish; Peeyush K Lala
Journal:  Cancer Sci       Date:  2014-09-11       Impact factor: 6.716

Review 6.  Cyclooxygenase-2: A Role in Cancer Stem Cell Survival and Repopulation of Cancer Cells during Therapy.

Authors:  Lisa Y Pang; Emma A Hurst; David J Argyle
Journal:  Stem Cells Int       Date:  2016-11-01       Impact factor: 5.443

7.  Convergent synthesis and evaluation of (18)F-labeled azulenic COX2 probes for cancer imaging.

Authors:  Donald D Nolting; Michael Nickels; Mohammed N Tantawy; James Y H Yu; Jingping Xie; Todd E Peterson; Brenda C Crews; Larry Marnett; John C Gore; Wellington Pham
Journal:  Front Oncol       Date:  2013-01-03       Impact factor: 6.244

8.  Selection of metastatic breast cancer cells based on adaptability of their metabolic state.

Authors:  Balraj Singh; Karen Tai; Simran Madan; Milan R Raythatha; Amanda M Cady; Megan Braunlin; LaTashia R Irving; Ankur Bajaj; Anthony Lucci
Journal:  PLoS One       Date:  2012-05-03       Impact factor: 3.240

9.  Prostaglandin E receptor EP4 is a therapeutic target in breast cancer cells with stem-like properties.

Authors:  Namita Kundu; Xinrong Ma; Tyler Kochel; Olga Goloubeva; Paul Staats; Keyata Thompson; Stuart Martin; Jocelyn Reader; Yukinori Take; Peter Collin; Amy Fulton
Journal:  Breast Cancer Res Treat       Date:  2013-11-27       Impact factor: 4.872

10.  A novel aspirin prodrug inhibits NFκB activity and breast cancer stem cell properties.

Authors:  Irida Kastrati; Vladislav A Litosh; Shuangping Zhao; Manuel Alvarez; Gregory R J Thatcher; Jonna Frasor
Journal:  BMC Cancer       Date:  2015-11-04       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.